This work showed in patients with pulmonary arterial hypertension, users of PDE-5 inhibitors compared to user’s endothelin receptor antagonists do not have a difference in ADRD risk as well as cell-based assays not showing amelioration of certain Alzheimer’s disease pathologies. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.